To additionally assess the impact of NKG2D blockade on a more potent mode of tumor killing involving immunotherapy, we used ICB-responsive B16-F10 melanomas treated concomitantly with αPD-1/4-1BB. The gene discussed is KLRK1; the disease is neoplasm.